These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7873382)

  • 1. The SCID mouse as a model for multiple myeloma.
    Ahsmann EJ; van Tol MJ; Oudeman-Gruber J; Lokhorst H; Uytdehaag FG; Schuurman HJ; Bloem AC
    Br J Haematol; 1995 Feb; 89(2):319-27. PubMed ID: 7873382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term engraftment of fresh human myeloma cells in SCID mice.
    Feo-Zuppardi FJ; Taylor CW; Iwato K; Lopez MH; Grogan TM; Odeleye A; Hersh EM; Salmon SE
    Blood; 1992 Dec; 80(11):2843-50. PubMed ID: 1450409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.
    Huang SY; Tien HF; Su FH; Hsu SM
    Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
    Sanchez E; Li M; Kitto A; Li J; Wang CS; Kirk DT; Yellin O; Nichols CM; Dreyer MP; Ahles CP; Robinson A; Madden E; Waterman GN; Swift RA; Bonavida B; Boccia R; Vescio RA; Crowley J; Chen H; Berenson JR
    Br J Haematol; 2012 Sep; 158(6):727-38. PubMed ID: 22804669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
    Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
    PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of a model for the homing of multiple myeloma cells to human bone marrow.
    Urashima M; Chen BP; Chen S; Pinkus GS; Bronson RT; Dedera DA; Hoshi Y; Teoh G; Ogata A; Treon SP; Chauhan D; Anderson KC
    Blood; 1997 Jul; 90(2):754-65. PubMed ID: 9226176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.
    Bueno C; Lopes LF; Greaves M; Menendez P
    Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients.
    Cassel A; Leibovitz N; Hornstein L; Quitt M; Aghai E
    Exp Hematol; 1990 Dec; 18(11):1171-3. PubMed ID: 2226677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of animal models in multiple myeloma.
    Libouban H
    Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SCID-hu myeloma model.
    Epstein J; Yaccoby S
    Methods Mol Med; 2005; 113():183-90. PubMed ID: 15968103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
    Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
    Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
    Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
    Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Establishment of xenotransplated mouse model using primary multiple myeloma cells].
    Liu CY; Zhang L; Wang N; Wang D; Geng Z; Xu DM; Li CR; Zhou JF; Huang L
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):195-9. PubMed ID: 22781606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.
    Huang YW; Richardson JA; Vitetta ES
    Cancer Res; 1995 Feb; 55(3):610-6. PubMed ID: 7834632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
    Rousselot P; Larghero J; Labaume S; Poupon J; Chopin M; Dosquet C; Marolleau JP; Janin A; Brouet JC; Fermand JP
    Eur J Haematol; 2004 Mar; 72(3):166-71. PubMed ID: 14962234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous monoclonal immunoglobulin-secreting peripheral blood mononuclear cells as a marker of disease severity in multiple myeloma.
    Cordoba F; Lavabre-Bertrand T; Salhi SL; Huguet MF; Gerfaux J; Rossi JF; Vendrell JP
    Br J Haematol; 2000 Mar; 108(3):549-58. PubMed ID: 10759713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice.
    Miyakawa Y; Ohnishi Y; Tomisawa M; Monnai M; Kohmura K; Ueyama Y; Ito M; Ikeda Y; Kizaki M; Nakamura M
    Biochem Biophys Res Commun; 2004 Jan; 313(2):258-62. PubMed ID: 14684154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.
    Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ
    Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.
    Yaccoby S; Epstein J
    Blood; 1999 Nov; 94(10):3576-82. PubMed ID: 10552969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.